Benzinga Bulls and Bears: GameStop, Marvell, Robinhood
Benzinga examined the prospects for many investors’ favorite stocks over the last week — here’s a look at some of our top stories.
Stocks · News reference
HSBC Downgrades Amgen to Hold, Lowers Price Target to $425
HSBC analyst Morten Herholdt downgrades Amgen (NASDAQ:AMGN) from Buy to Hold and lowers the price target from $445 to $425.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Amgen vs. CRISPR Therapeutics: Which Healthcare Stock Is a Better Buy in 2026?
The article compares Amgen, an established pharmaceutical giant with $36.7B in revenue and a 2.60% dividend yield, against CRISPR Therapeutics, a gene-editing biotech pioneer with only $3.5M in revenue but groundbreaking CASGEVY therapy. While CRISPR offers high-growth potential, it remains unprofitable with significant losses. The author recommends Amgen for most investors seeking stability and predictable returns, though acknowledges CRISPR's improving commercial trajectory makes it a more compelling speculative opportunity than previously.
Pyxis Oncology Stock Soars Over 5% Overnight: Here's What You Need to Know
Pyxis Oncology shares gained 9.25% after hours following a leadership update and ahead of Wednesday’s clinical data webcast.